You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Johnson and Johnson

Last Updated: April 2, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203661

Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 203661 describes CEFAZOLIN SODIUM, which is a drug marketed by Abraxis Pharm, Acs Dobfar, Aurobindo Pharma, Bedford, Cephazone Pharma, Dr Reddys, Facta Farma, Fresenius Kabi Usa, Glaxosmithkline, Hikma Farmaceutica, Hospira Inc, Qilu, Samson Medcl, Sandoz, Steri Pharma, Teva Pharms, and West-ward Pharms Int, and is included in thirty-two NDAs. It is available from fourteen suppliers. Additional details are available on the CEFAZOLIN SODIUM profile page.

The generic ingredient in CEFAZOLIN SODIUM is cefazolin sodium. There are twenty-seven drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the cefazolin sodium profile page.
Summary for 203661
Ingredient:cefazolin sodium
Formulation / Manufacturing:see details
Pharmacology for NDA: 203661
Medical Subject Heading (MeSH) Categories for 203661
Suppliers and Packaging for NDA: 203661
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CEFAZOLIN SODIUM cefazolin sodium INJECTABLE;INJECTION 203661 ANDA General Injectables & Vaccines, Inc. 52584-087 52584-087-00 1 VIAL, SINGLE-DOSE in 1 BAG (52584-087-00) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE
CEFAZOLIN SODIUM cefazolin sodium INJECTABLE;INJECTION 203661 ANDA Apotex Corp. 60505-6142 60505-6142-5 25 VIAL, SINGLE-DOSE in 1 CARTON (60505-6142-5) > 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE (60505-6142-0)

Profile for product number 001

Approval Date:Dec 28, 2015TE:APRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.